StockNews.AI
CRBU
StockNews.AI
187 days

Caribou Biosciences, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

1. Investors in CRBU may join a class action lawsuit regarding misleading statements. 2. Allegations involve overstating CAR-T therapy results and financial stability risks. 3. Significant claims against CRBU could affect future funding and operations. 4. Shareholders can register until February 24, 2025 for possible lead plaintiff status.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The lawsuit's allegations suggest a potential decline in investor confidence, similar to past cases involving pharmaceutical firms reporting inaccurate clinical trial results.

How important is it?

The allegations could impact CRBU's credibility and stock performance significantly; class action lawsuits often lead to substantial adjustments in stock value.

Why Short Term?

Legal issues tend to influence stock price immediately, as seen with other biotech companies facing litigation.

Related Companies

CRBUNASDAQ
, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU). Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=128936&from=4 CLASS PERIOD: July 14, 2023 to July 16, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) they had overstated CB-010's safety, efficacy, and durability relative to approved autologous CAR-T cell therapies in treating patients with r/r B-NHL and/or LBCL, as well as CB-010's overall clinical results and commercial prospects; (ii) Caribou was at significant risk of having insufficient cash, liquidity, and/or other capital to fund its current business operations, including preclinical research activities associated with the allogeneic CAR-NK platform; (iii) all the foregoing was likely to have a significant negative impact on Caribou's business and operations; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times. DEADLINE: February 24, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=128936&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of CRBU during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is February 24, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected]Phone: (646) 453-8903 SOURCE The Gross Law Firm WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News